Generic Olopatadine and Olopatadine HCL Looks Promising

Generic Olopatadine and Olopatadine HCL Looks Promising

allergic-conjunctivitisOlopatadine CAS# 113806-05-6 & Olopatadine Hydrochloride CAS# 140462-76-6, are also known as Patanol and Pataday, which are marketed by Alcon. With the patent for olopatadine due to expire on June 6, 2015, researchers are looking forward to offering generic options of this popular allergy remedy. Olopatadine is effectual as an ophthalmic solution in the form of eye drops, often prescribed for the commonly diagnosed allergic conjunctivitis. Patanol is available in a 5 milliliter “droptainer”. Pataday, or olopatadine hydrochloride, is appropriate for patients experiencing ocular itching associated with allergic conjunctivitis, and is available in a 2.5 milliliter fill in a 4 milliliter bottle.

Side effects of olopatadine hydrochloride are few, with approximately 10 percent of patients reporting pharyngitis after use. Less then 5 percent of patients reported ocular problems, such as lid edema and blurred vision.  About 7 percent of patients dosed  with olopatadine complained of headache, and less then 5 percent of patients reported adverse ocular effects, such as dry eye, burning and stinging. It should be noted by prescribers that Pataday solution has twice the concentration of Patanol, and is to be used once daily by patients experiencing ocular itching.

OlopatadineA wide variety of causes contribute to cases of allergic conjunctivitis. These include high pollen counts, hay fever, allergies to dust mites and animal dander, and eczema related conditions due to allergies. According to the CDC, high pollen counts which are reported seasonally are a primary cause of itching and discomfort associated with allergic conjunctivitis. The American Academy of Allergy, Asthma & Immunology reports that 54.6 percent of the U.S. population tests positive to one or more allergens, with allergic diseases effecting up to 50 million Americans. As the most common allergy affecting the eye, allergic conjunctivitis is not only frustrating for patients, but it also negatively effects the patient quality of life. A generic formulation of widely used olopatadine & olopatadine hydrochloride is sure to have patients seeing a brighter future ahead.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service